Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
Status:
Completed
Trial end date:
2021-07-06
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to assess the relative bioavailability of
risankizumab in on-body delivery system (OBDS) versus the prefilled syringe (PFS) (Substudy
1) and to assess the relative bioavailability of risankizumab in the to-be-marketed Dose A
liquid vial versus the Dose B liquid vial used in the Phase 3 studies (Substudy 2).